In its rush for the next breakthrough, the field of psychiatry often discards older, effective treatments due to historical stigma. For instance, MAO inhibitors and modern, safer Electroconvulsive Therapy (ECT) are highly effective for specific depression types but are underutilized because of past negative associations, a phenomenon driven more by politics than science.

The American medical system's emphasis on 15-minute visits and efficiency incentivizes prescribing medication to treat symptoms rather than unraveling root causes. This approach aims to "polish the hood when there's a problem in the engine."

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

The history of depression treatment shows a recurring pattern: a new therapy (from psychoanalysis to Prozac) is overhyped as a cure-all, only for disappointment to set in as its limitations and side effects become clear. This cycle of idealization then devaluation prevents a realistic assessment of a treatment's specific uses and downsides.

A key unmet need in psychiatry is the lack of disease-modifying options. An orthopedic doctor has a full toolbox—from NSAIDs to injections to surgery—to treat both symptoms and the underlying condition. In contrast, psychiatrists are largely limited to pills offering temporary symptomatic relief without addressing core pathology.

The widespread belief that depression stems from a chemical imbalance was a successful marketing hypothesis by drug companies, not a scientifically proven fact. After 60 years of research, no consistent evidence supports the theory, yet it drove massive antidepressant adoption.

Contrary to the idea that all therapy is bespoke, highly effective "manualized" treatments exist with standardized protocols for issues like depression. However, most therapy consumers are unaware of this and don't know to ask for a specific, evidence-based approach from their provider.

A critical difference between medication and therapy is durability. Studies show when antidepressants are discontinued, depression often returns because the patient hasn't learned new behaviors or coping strategies. Therapy aims to build these skills, making its effects longer-lasting.

When patients stop antidepressants, they often experience severe withdrawal symptoms like panic attacks and insomnia. Doctors, trained to look for relapse, frequently misinterpret these as a return of the underlying illness, creating a cycle of unnecessary long-term medication.